Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2022)
✉ Email this page to a colleague
AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2022)
| Docket | ⤷ Subscribe | Date Filed | 2022-04-26 |
| Court | District Court, N.D. West Virginia | Date Terminated | 2023-03-08 |
| Cause | 35:271 Patent Infringement | Assigned To | John Preston Bailey |
| Jury Demand | None | Referred To | Robert W. Trumble |
| Patents | 10,166,247; 7,759,328; 8,143,239; 8,575,137 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-04-26 | 1 | Complaint (NOT for attorney use) | the ’328 patent”), 8,143,239 (“the ’239 patent”), 8,575,137 (“the ’137 patent”), and 10,166,247 (“the ’… This is a civil action for patent infringement arising under the patent laws of the United States, …prior to the expiration of U.S. Patent No. 11,311,558 (“the ’558 patent”). Plaintiffs seek injunctive … The Patent-in-Suit 11. The ’558 patent, entitled “Composition for … 12. The ’558 patent is related through continuation applications to U.S. Patent Nos. 7,759,328 ( | External link to document |
| 2022-11-23 | 204 | Memorandum & Opinion | 8,143,239, 8,575,137, and 10,166,247 that were the subject of two prior trials before Judge Keeley, … Specifically, the patent at issue is U.S. Patent No. 11,311,558 (“the patent-in-suit”). AstraZeneca…ORDER This patent infringement case involves one (1) United States Patent issued to AstraZeneca…”), and rhinitis. The patent-in-suit shares a specification with U.S. Patent Nos. 7,759,328, 8,143,239…the ‘247 patent. [Id. at 5]. In its second letter, Mylan also asserted that the ‘247 patent was invalid | External link to document |
| 2022-12-05 | 223 | Memorandum & Opinion AND Order (SEALED) AND Order on Sealed Motion (SEALED) AND Order on Motion for Partial Summary Judgment | 8,143,239, 8,575,137, and 10,166,247 that were the subject of two prior trials before Judge Keeley, but…. Specifically, the patent at issue is U.S. Patent No. 11,311,558 (“the patent-in-suit”). AstraZeneca…case, the patent-in-suit is a patent “for a drug ... the use of which is claimed in a patent,” 35 U.S.C…ORDER This patent infringement case involves one (1) United States Patent issued to AstraZeneca…”), and rhinitis. The patent-in-suit shares a specification with U.S. Patent Nos. 7,759,328, 8,143,239 | External link to document |
| 2022-06-01 | 30 | Memorandum in Support of Motion | certification to a fourth patent, U.S. Patent No. 10,166,247 (“’247 patent”) from the same family as …under it. The patent at issue in this case, U.S. Patent No. 11,311,558 (“’558 patent”) was not even…the only patents then-listed in FDA’s Orange Book, U.S. Patent Nos. 7,759,328 (“’328 patent”), 8,143,239…BACKGROUND A. THE PATENT-IN-SUIT The ’558 patent, titled “Composition for Inhalation…See ECF No. 1-2 (’558 patent) at 1:5-37; see also Compl. ¶ 11. The ’558 patent issued on April 26, 2022 | External link to document |
| 2022-07-12 | 53 | Memorandum & Opinion AND Order on Motion to Dismiss for Failure | the ‘328 patent”), 8,143,239 (“the ‘239 patent”), 8,575,137 (“the ‘137 patent”), and 10,166,247 (“the ‘… ‘247 patent”). Like the ‘558 patent, all four patents are directed to formulations of budesonide and…Complaint, Plaintiffs allege patent infringement arising under the patent laws of the United States, 35…Infringement of the ‘558 Patent and (2) Declaratory Judgment of Infringement of the ‘558 Patent. See [Id. at 11… and proper. A. The Patent-in-Suit The ‘558 patent, entitled “Composition for Inhalation | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
